RiboQuark Pharmaceutical

RiboQuark Pharmaceutical is a clinical-stage biotechnology company specializing in the development of RNA interference (RNAi) therapeutics. Founded in 2012 as a joint venture between Suzhou Ribo Life Science and Quark Pharmaceuticals, the company is headquartered in Kunshan, China. Its primary focus is on addressing unmet medical needs in ophthalmology and dermatology using small interfering RNA (siRNA) technology. The lead product candidate, QPI-1007, is an ocular neuroprotectant targeting Caspase 2, which has been evaluated in Phase 2/3 clinical trials for non-arteritic anterior ischemic optic neuropathy (NAION) and glaucoma. Additionally, the company is advancing programs for alopecia and other conditions such as cancer and lung injury.